

Diagnostics Advisory Committee Interests Register

Topic: CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

Publication date: July 2024

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Daniel Burrage	Specialist committee member	Financial	Co-author of textbook 'The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing' (Elsevier) which includes information on the clinical pharmacology and prescribing of antiplatelet drugs such as clopidogrel	2014	August 2022	Ongoing	<i>Declare and participate, Chair and AD 29032023</i>
Daniel Burrage	Specialist committee member	Non financial professional and personal interests	Contributing author to journal article: "The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy" Magavern, E.F., Kaski, J.C., Turner, R.M., Drexel, H., Janmohamed, A., Scourfield, A., Burrage, D., Floyd, C.N., Adeyeye, E., Tamargo, J. and Lewis, B.S., 2022. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal-Cardiovascular Pharmacotherapy, 8(1), pp.85-99.	2021	August 2022	2022	<i>Declare and participate, Chair and AD 29032023</i>
Mark Cadman	Specialist committee member	Financial	PPI Representative on a Stroke Association funded Project at Glasgow Caledonian University (HEADS: UP, Trial Advisory Group).	July 2019	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
Mark Cadman	Specialist committee member	Financial	Lay Member of the NICE Stroke Rehab. Guideline Committee.	Jan 2021	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
Mark Cadman	Specialist committee member	Non-financial professional and personal interests	Trustee of Harlow Stroke Support	May 2017	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>

Mark Cadman	Specialist committee member	Non-financial professional and personal interests	Ambassador for the Stroke Association	April 2015	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
-------------	-----------------------------	---	---------------------------------------	------------	----------	---------	---

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mark Cadman	Specialist committee member	Non-financial professional and personal interests	Member of the Stroke Association's Voices in Stroke Research Panel	Sept 2016	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
Mark Cadman	Specialist committee member	Non-financial professional and personal interests	Lead Volunteer on my local NHS Stroke Rehabilitation Ward	June 2016	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
Mark Cadman	Specialist committee member	Non-financial professional and personal interests	Fellow of the Chartered Institute of Purchasing & Supply	Jan 2009	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
Mark Cadman	Specialist committee member	Non-financial professional and personal interests	Registered Member and subsequently individual member of the British Association of Counselling & Psychotherapy	October 2019	May 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
Alexander Doney	Specialist committee member	Non financial professional and personal interests	I have published in this area eg PMID: 28653333; This paper demonstrated that stroke patients who are slow or intermediate metabolisers of clopidogrel seem to be at higher risk of recurrent major adverse cardiovascular events when treated with clopidogrel compared to normal clopidogrel metabolisers. I did not hold a particular view in this paper but simply described the evidence generated from the study. I have also contributed to other publications in this area and will be contributing to future publications. PMID: 20557312 and PMID: 29468659	2018	August 2022	Indefinite	<i>Declare and participate, Chair and AD 29032023</i>
Alexander Doney	Specialist committee member	Non financial professional and personal interests	I have a significant academic track record in Precision Medicine research and implementation in general and I am the Director for a Masters Programme In Healthcare Data Science for Applied Precision Medicine at the University of Dundee Medical School. Pharmacogenetic testing for clopidogrel is a major exemplar within the Pharmacogeomics theme.	2021	August 2022	Indefinite	<i>Declare and participate, Chair and AD 29032023</i>
Alexander Doney	Specialist committee member	Indirect	I sit on the Scottish Pharmacogenomics Working Group for the National Services Division of NHS National Services Scotland. The remit of this group is to "to advise regarding the strategic integration of pharmacogenomic testing into routine NHSS practice to provide patients	Jan 2021	August 2022	Indefinite	<i>Declare and participate, Chair and AD 29032023</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			with safer and more appropriate therapies and to avoid wasting time and money on treatments that will be at best ineffective and at worst harmful". This is for pharmacogenetic testing in general in the NHS. However, I have submitted a paper to the Group suggesting CYP2C19 testing for clopidogrel as an exemplar for this group.				
Alexander Doney	Specialist committee member	Indirect	As a Stroke Consultant in the NHS I lead an initiative in NHS Tayside for testing CYP2C19 status for all patients who develop a new indication for clopidogrel. This initiative was part funded by the DataLabs as part of an innovation project as well as innovation funding from NHS Tayside. In this case I hold the clinical view (based on my own and wide-spread other clinical evidence) that pharmacogenetic testing for clopidogrel is in the interests of stroke patients who are indicated for clopidogrel treatment.	2019	August 2022	Indefinite	<i>Declare and participate, Chair and AD 29032023</i>
Alexander Doney	Specialist committee member	Indirect	As part of my wider programme of research I am engaged in collaborative discussions with companies who provide pharmacogenomic solutions, such as genotyping (eg Illumina and Thermo Fisher) and clinical Decision support (eg. MyDNA and STORM ID). These companies are part of either existing or future precision medicine implementation research studies that I am involved in or developing. Testing for clopidogrel metabolism status is an integral component of more broad precision medicine implementation in these studies	2022	August 2022	Indefinite	<i>Declare and participate, Chair and AD 29032023</i>
Salim Elyas	Specialist committee member	Financial	Speaker fees for Bayer PLC Presented a talk on Stroke and TIA update in 2019 and 2020	2019/2020	June 2022	2019/2020	<i>Reviewed at time of application, declare and participate</i>
Salim Elyas	Specialist committee member	Financial	Speaker fees for Pfizer UK Ltd Presented a talk on Stroke and TIA update	2019	June 2022	2019	<i>Reviewed at time of application, declare and participate</i>
Salim Elyas	Specialist committee member	Financial	Clinical Adviser for Enginsoft UK Ltd which is an engineering company specialized in developing predictive models using artificial intelligence and machine learning	August 2021	June 2022	September 2021	<i>Reviewed at time of application, declare and participate</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Salim Elyas	Specialist committee member	Non financial professional and personal interests	Member of data monitoring committee for the ProMOTe study, This research study explored the use of a urine test to help predict subsequent strokes in TIA patients	February 2016	June 2022	June 2017	<i>Reviewed at time of application, declare and participate</i>
Salim Elyas	Specialist committee member	Non financial professional and personal interests	Co-Investigator for the Early detection of neuronal loss in stroke patients (NEURASS study). This a feasibility study to identify a humoral biomarker for stroke patients using cell free DNA.	October 2019	June 2022	Ongoing	<i>Reviewed at time of application, declare and participate</i>
Salim Elyas	Specialist committee member	Non financial professional and personal interests	Principal Investigator for the NAVIGATE ESUS study which explored the role of using Rivaroxaban (anticoagulant) in patient with embolic stroke of uncertain source (ESUS). Results published in NEJM 2018	December 2014	June 2022	January 2019	<i>Reviewed at time of application, declare and participate</i>
Salim Elyas	Specialist committee member	Indirect	EnginSoft UK Ltd is developing an AI and machine learning system to help GPs identify high risk patients who are at risk of developing strokes	August 2021	June 2022	October 2021	<i>Reviewed at time of application, declare and participate</i>
Salim Elyas	Specialist committee member	Non financial professional and personal interests	Chief Investigator for LIBREXIA-STROKE study (A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High Risk Transient Ischemic Attack).		24 March 2023		<i>Declare and participate, Chair and AD 29032023</i>
Albert Ferro	Specialist committee member	Non financial professional and personal interests	Published invited review in British Journal of Clinical Pharmacology entitled "Antiplatelet therapy in cardiovascular disease: current status and future directions". J Clin Pharmacol 2022; 88:2686-2699	2022	August 2022		<i>Declare and participate, Chair and AD 29032023</i>
Dheeraj Kalladka	Specialist committee member	Non financial professional and personal interests	Stroke Advisory Committee Member for Association of British Neurologists (ABN)	March 2021		Ongoing	
Dheeraj Kalladka	Specialist committee member	Non financial professional and personal interests	Author/Clinical Trial Investigator: Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 2018; 379:215-225 DOI: 10.1056/NEJMoa1800410	2018	June 2022		<i>Declare and participate, Chair and AD 29032023</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dheeraj Kalladka	Specialist committee member	Non financial professional and personal interests	Author/Clinical Trial Investigator: Antiplatelet therapy for transient ischaemic attack and minor ischaemic stroke. Br J Hosp Med (Lond). 2020 Jun 2; 81(6):1-3. doi: 10.12968/hmed.2020.0121. https://doi.org/10.12968/hmed.2020.0121	2020	June 2022		<i>Declare and participate, Chair and AD 29032023</i>
Dheeraj Kalladka	Specialist committee member	Non financial professional and personal interests	Author/Clinical Trial Investigator: Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet. 2019 Jun 29; 393(10191):2613-2623. doi: 10.1016/S0140-6736(19)30840-2.	2019	June 2022		<i>Declare and participate, Chair and AD 29032023</i>
Dagan Lonsdale	Specialist committee member		Invited speaker for Gilead at educational event on antifungals. I have been offered a fee, which I have declined	September 2022	September 2022	September 2022	<i>Declare and participate, Chair and AD, Sept 2022</i>
Paresh Parmar	Specialist committee member	None	-				
Michelle Wood	Specialist committee member	Indirect	Member of the national pharmacogenomic group in Wales advising on testing strategy for pharmacogenomic testing in Wales	October 2021	September 2022		<i>Reviewed at time of application, declare and participate</i>